Urology Cancer Center PC

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Prostate cancer8 trials
• Colorectal cancer1 trial
• Head and neck cancer1 trial
• Melanoma1 trial
• Multiple myeloma1 trial

Phase

• Phase 36 trials
• Phase 23 trials
• Phase 1/22 trials
• Phase 41 trial

Status

• Active, not recruiting7 trials
• Completed3 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals5 trials
• Janssen Research & Development, LLC2 trials
• National Cancer Institute (NCI)2 trials
• SWOG Cancer Research Network2 trials
• POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company1 trial

Running trials

• Active, not recruiting

  An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

  NCT06894511· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  NCT06800313· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

  NCT05849298· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  NCT05803941· Phase 4· Novartis Pharmaceuticals· Source

  Contact: Luke Nordquist (principal investigator)

• Active, not recruiting

  An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

  NCT04647526· Phase 3· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting

Closed trials

• Completed

  177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

  NCT01668719· Phase 1/2· SWOG Cancer Research Network· Source